Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Samuel Caughron"'
Autor:
Liudmila Schafer, Matthew Aboudara, Ossama Tawfik, Janakiraman Subramanian, John Borsa, Samuel Caughron, Sreeni Jonnalagadda, Eric Ewing, Pradip Mana, Timothy Saettele
Publikováno v:
Archives of pathologylaboratory medicine. 146(5)
Context.— Precision therapies for patients with driver mutations can offer deep and durable responses that correlate with diagnosis, metastasis prognosis, and improvement in survival. The use of such targeted therapies will continue to increase, pu
Autor:
Tara L. Burke, Sarah A. Thibault-Sennett, Anthony N. Sireci, Jay Patel, Loren Joseph, Oana Rosca, Dara L. Aisner, Matthew C. Hiemenz, Samuel Caughron
Publikováno v:
The Journal of Molecular Diagnostics : JMD
Widespread indications for use of molecular diagnostics in various aspects of clinical medicine have driven proliferation of testing. The rapid adoption and continuous technological evolution of molecular diagnostics have often strained the developme
Autor:
Pranil Chandra, Elaine Lyon, Roger D. Klein, Jill M. Hagenkord, Milena Cankovic, Rajyasree Emmadi, Paul G. Rothberg, Kay E. Jewell, Robyn L. Temple-Smolkin, Samuel Caughron, Victoria M. Pratt, Stephanie Hallam, Loren Joseph
Publikováno v:
The Journal of Molecular Diagnostics. 18:605-619
Clinical utility describes the benefits of each laboratory test for that patient. Many stakeholders have adopted narrow definitions for the clinical utility of molecular testing as applied to targeted pharmacotherapy in oncology, regardless of the po
Autor:
Loren, Joseph, Milena, Cankovic, Samuel, Caughron, Pranil, Chandra, Rajyasree, Emmadi, Jill, Hagenkord, Stephanie, Hallam, Kay E, Jewell, Roger D, Klein, Victoria M, Pratt, Paul G, Rothberg, Robyn L, Temple-Smolkin, Elaine, Lyon
Publikováno v:
The Journal of molecular diagnostics : JMD. 18(5)
Clinical utility describes the benefits of each laboratory test for that patient. Many stakeholders have adopted narrow definitions for the clinical utility of molecular testing as applied to targeted pharmacotherapy in oncology, regardless of the po
Autor:
Debra G.B. Leonard, James M. Crawford, Allison M. Cushman-Vokoun, Samuel Caughron, John D. Pfeifer, Alexis B. Carter, Sophia Yohe
Publikováno v:
Archives of pathologylaboratory medicine. 139(11)
ContextNext-generation sequencing performed in a clinical environment must meet clinical standards, which requires reproducibility of all aspects of the testing. Clinical-grade genomic databases (CGGDs) are required to classify a variant and to assis
Autor:
Samuel Caughron, Lynn Bry, James M. Crawford, Jeffrey A. Kant, John D. Pfeifer, Jill H. Kaufman, Stephen Black-Schaffer
Publikováno v:
Genetics in medicine : official journal of the American College of Medical Genetics. 16(12)
The practice of “genomic” (or “personalized”) medicine requires the availability of appropriate diagnostic testing. Our study objective was to identify the reasons for health systems to bring next-generation sequencing into their clinical lab